

Fatty Liver Is Independently Associated With Alterations in Circulating HDL₂ and HDL₃ Subfractions

KONSTANTINOS KANTARTZIS, MD¹
 KILIAN RITTIG, MD¹
 ALEXANDER CEGAN, PHD¹
 JÜRGEN MACHANN, PHD²
 FRITZ SCHICK, PHD²

BERND BALLETSCHOFER, MD¹
 ANDREAS FRITSCHKE, MD¹
 ERWIN SCHLEICHER, PHD¹
 HANS-ULRICH HÄRING, MD¹
 NORBERT STEFAN, MD¹

Fatty liver is associated with insulin resistance, atherosclerosis, and the metabolic syndrome (1–7) and predicts future cardiovascular events (4–8). The pro-atherogenic serum lipid profile in subjects with fatty liver is characterized by elevated levels of triglycerides, low HDL cholesterol, and an increase in small dense LDL particles (9–12). Regarding HDL, not only quantitative, but also qualitative and compositional alterations are related to its antiatherogenic properties (13–16). In particular, circulating HDL₂ was found to protect from atherosclerosis (17,18). In the present study, we first investigated whether fatty liver is associated with altered circulating HDL cholesterol subfractions and second whether this relationship is independent of insulin sensitivity, thus possibly representing a direct link between fatty liver and cardiovascular disease.

RESEARCH DESIGN AND METHODS

— In our ongoing study on the pathophysiology of type 2 diabetes, ~300 Caucasians were carefully characterized for fatty liver and its associated metabolic characteristics (19). To select a subgroup that was representative for the percentage of subjects having fatty liver (liver fat >5.56%) (20) in our large cohort (~40%) and in whom enough sample volume was available to measure the

HDL cholesterol subfractions, we randomly selected 8 men and 8 women with fatty liver and 24 control subjects.

The subjects underwent a 75-g oral glucose tolerance test to exclude diabetes and calculate insulin sensitivity (21). Total body fat was measured by bioelectrical impedance, visceral fat by magnetic resonance (MR) tomography, and liver fat by ¹H-MR spectroscopy (19). Serum total, HDL, and LDL cholesterol, as well as triglyceride concentrations, were measured by standard colorimetry, plasma adiponectin by radioimmunoassay, and apolipoprotein (apo)B₁₀₀ and apoA-1 by immunonephelometry. Circulating HDL₂ and HDL₃ cholesterol levels were quantified after ultracentrifugation of 1.5 ml serum (22), and the fatty acid pattern of these subfractions was determined by gas chromatography (23) within the entire particle, thereafter, in a subgroup of 34 subjects in whom sufficient sample volume was available after ultracentrifugation and chemical derivatization. A total of 15 subjects had fatty liver, and 19 were control subjects. Intima-media thickness (IMT) of the carotid artery was measured by high-resolution ultrasound. Relationships between parameters were tested using univariate correlations, and multivariate linear regression models were used to investigate independent re-

lationships. $P \leq 0.05$ was considered statistically significant.

RESULTS — Altogether, 25 women and 15 men were studied. While age ($P = 0.08$) and total body fat ($P = 0.23$) were not different between subjects with fatty liver and control subjects, individuals with fatty liver had higher body weight ($P = 0.02$), BMI ($P = 0.002$), waist circumference ($P = 0.003$), and visceral fat ($P < 0.0001$), as well as higher IMT ($P = 0.04$). Furthermore, they had higher fasting ($P = 0.006$) and 2-h ($P = 0.01$) glycemia and insulinemia (both $P < 0.0001$) and lower plasma adiponectin levels and insulin sensitivity (Table 1).

As expected, subjects with fatty liver had higher circulating triglyceride and apoB₁₀₀ and lower HDL cholesterol levels. Interestingly, the largest differences between subjects with fatty liver and control subjects were found for circulating HDL₂ cholesterol and the HDL₂-to-HDL₃ cholesterol ratio. No difference in HDL₃ cholesterol levels was observed between the groups (Table 1).

We next investigated whether the differences in the HDL subfractions between the two groups were independent of insulin sensitivity and adiponectin. Only circulating HDL₂ cholesterol and the HDL₂-to-HDL₃ cholesterol ratio remained statistically different between the groups after adjustment for these determinants (insulin sensitivity [Table 1] and adiponectin, $P = 0.036$ and $P = 0.01$, respectively). Power calculations revealed that we had a power of 94% to detect a difference in circulating HDL₂ cholesterol between the subjects with fatty liver and control subjects at the α level of 0.05. Nevertheless, to further validate our novel findings and to exclude a type 1 error that frequently may occur when using dichotomous analyses, we also used continuous variables for analyses. The strongest relationships, and the only ones that remained statistically significant after additional adjustment for insulin sensitivity (Table 1), as well as adiponectin, were those of liver fat with the HDL₂ cholesterol levels and the HDL₂-to-HDL₃ cholesterol ratio (insulin sensitivity [Table 1]

From the ¹Department of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Medicine, Nephrology, and Clinical Chemistry, University of Tübingen, Tübingen, Germany; and the ²Section on Experimental Radiology, University of Tübingen, Tübingen, Germany.

Address correspondence and reprint requests to Norbert Stefan, MD, University of Tübingen, Department of Internal Medicine, Otfried-Müller-Str. 10, D-72076 Tübingen, Germany. E-mail: norbert.stefan@med.uni-tuebingen.de.

Received for publication 7 August 2007 and accepted in revised form 1 November 2007.

Published ahead of print at <http://care.diabetesjournals.org> on 13 November 2007. DOI: 10.2337/dc07-1558.

K.K. and K.R. contributed equally to this work.

Abbreviations: apo, apolipoprotein; IMT, intima-media thickness.

© 2008 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Table 1—Serum lipids, insulin sensitivity, and circulating adiponectin in subjects with fatty liver and in control subjects, as well as correlations of these characteristics with liver fat as a continuous variable

| | Fatty liver (n = 16) | Control subjects (n = 24) | P | P* | Liver fat | | | |
|---------------------------------------|-------------------------|------------------------------|---------|-------|-----------|---------|-------|-------|
| | | | | | r | P | r* | P* |
| Triglyceride (mg/dl) | 171 ± 29 | 92 ± 8 | 0.003 | 0.21 | 0.47 | 0.002 | 0.22 | 0.18 |
| Cholesterol (mg/dl) | | | | | | | | |
| Total | 194 ± 9 | 179 ± 6 | 0.16 | 0.66 | 0.18 | 0.25 | 0.005 | 0.98 |
| LDL | 127 ± 8 | 111 ± 5 | 0.09 | 0.76 | 0.26 | 0.11 | 0.03 | 0.86 |
| HDL | 45 ± 2 | 55 ± 3 | 0.02 | 0.22 | −0.44 | 0.005 | −0.31 | 0.06 |
| HDL ₂ | 4.7 ± 0.4 | 8.5 ± 0.9 | 0.0008 | 0.049 | −0.54 | 0.0003 | −0.37 | 0.02 |
| HDL ₃ | 22.2 ± 1.0 | 22.7 ± 0.9 | 0.70 | 0.23 | −0.12 | 0.46 | 0.11 | 0.51 |
| HDL ₂ -to-HDL ₃ | 0.21 ± 0.01 | 0.37 ± 0.03 | 0.0001 | 0.004 | −0.58 | <0.0001 | −0.48 | 0.002 |
| ApoAI (mg/dl) | 139 ± 4 | 150 ± 5 | 0.12 | 0.28 | −0.28 | 0.08 | −0.23 | 0.17 |
| ApoB (mg/dl) | 102 ± 5 | 85 ± 3 | 0.009 | 0.49 | 0.41 | 0.009 | 0.11 | 0.51 |
| Insulin sensitivity (AU) | 7.5 ± 0.9 | 19.1 ± 1.4 | <0.0001 | — | −0.77 | <0.0001 | — | — |
| Adiponectin (μg/ml) | 9.3 ± 0.7 | 14.2 ± 1.0 | 0.0002 | 0.28 | −0.48 | 0.002 | −0.03 | 0.84 |

Data are means ± SD. *Additionally adjusted for insulin sensitivity. AU, arbitrary units.

and adiponectin, $P = 0.01$ and $P = 0.005$, respectively). The association of liver fat with total HDL cholesterol remained statistically significant after adjustment for adiponectin ($P = 0.02$) but not for insulin sensitivity (Table 1).

IMT, an early marker of atherosclerosis, correlated strongly with HDL₂ cholesterol ($r = -0.51$, $P = 0.001$) and weaker with total HDL cholesterol ($r = -0.47$, $P = 0.003$), HDL₃ cholesterol ($r = -0.42$, $P = 0.008$), and the HDL₂-to-HDL₃ cholesterol ratio ($r = -0.45$, $P = 0.005$). These correlations were independent of insulin sensitivity (HDL₂ cholesterol, $r = -0.44$, $P = 0.005$; total HDL cholesterol, $r = -0.41$, $P = 0.01$; HDL₃ cholesterol, $r = -0.37$, $P = 0.02$; and HDL₂-to-HDL₃ cholesterol ratio, $r = -0.38$, $P = 0.02$) or adiponectin (HDL₂ cholesterol, $r = -0.53$, $P = 0.0007$; total HDL cholesterol, $r = -0.46$, $P = 0.004$; HDL₃ cholesterol, $r = -0.41$, $P = 0.01$; and HDL₂-to-HDL₃ cholesterol ratio, $r = -0.46$, $P = 0.003$). Finally, we addressed potential mechanisms that may render HDL₂ more potent in the prevention of atherosclerosis than HDL₃. Besides lipoprotein-associated phospholipase A₂ and its product lysophosphatidylcholine (24), the enzyme paraoxonase 1 has a critical role in the antiatherosclerotic properties of HDL particles (13). Because the latter enzyme is inactivated by saturated but not unsaturated fatty acids (25), we investigated whether the fatty acid pattern within the HDL subfractions differed. Indeed, the HDL₂ subfraction contained a higher percentage of unsaturated fatty acids than the HDL₃ subfraction ($P < 0.0001$). Similar results were obtained

when we performed these analyses separately within the subjects with fatty liver and the control subjects (both $P < 0.0001$). Since we analyzed fatty acids in the entire HDL particle, and lipid subgroups differ between HDL₂ and HDL₃, it remains to be established whether the fatty acid pattern differs within the isolated lipid subgroups.

CONCLUSIONS— In the present study, we provide novel information that liver fat correlates stronger with circulating HDL₂ cholesterol and the HDL₂-to-HDL₃ cholesterol ratio than with total HDL cholesterol. The correlations of liver fat with HDL₂ cholesterol and the HDL₂-to-HDL₃ cholesterol ratio remained statistically significant even after adjustment for whole-body insulin resistance, the major underlying abnormality that drives dyslipidemia (11,12), and circulating adiponectin, which is associated with both dyslipidemia and liver fat. In contrast, the associations of liver fat with triglycerides and circulating total HDL cholesterol, as well as circulating apoB, were rendered nonsignificant after correction for insulin resistance. Thus, the present findings provide evidence that circulating HDL₂, which is the more potent antiatherogenic HDL subfraction (17,18), and upon our preliminary analyses contained lipids with a higher amount of unsaturated fatty acids than HDL₃, is more suppressed than total HDL in subjects with fatty liver. These data further imply that determination of HDL₂ cholesterol, in addition to total HDL cholesterol, may more precisely predict the actual risk for cardiovascular events in subjects with fatty liver.

References

1. Roden M: Mechanisms of disease: hepatic steatosis in type 2 diabetes: pathogenesis and clinical relevance. *Nat Clin Pract Endocrinol Metab* 2:335–348, 2006
2. Yki-Järvinen H, Westerbacka J: The fatty liver and insulin resistance. *Curr Mol Med* 5:287–295, 2005
3. Tolman KG, Fonseca V, Dalpiaz A, Tan MH: Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. *Diabetes Care* 30:734–743, 2007
4. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G: Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. *Hepatology* 42:473–480, 2005
5. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G: Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. *Diabetes Care* 29:1325–1330, 2006
6. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E: Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. *Arterioscler Thromb Vasc Biol* 25:1045–1050, 2005
7. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care* 30:1212–1218, 2007
8. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G: Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. *Diabetes* 54:3541–

- 3546,2005
9. Ginsberg HN, Zhang Y-L, Hernandez-Ono A: Metabolic syndrome: focus on dyslipidemia. *Obesity* 14 (Suppl.):41S–49S, 2006
 10. Toledo FG, Sniderman AD, Kelley DE: Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. *Diabetes Care* 29: 1845–1850, 2006
 11. Taskinen MR: Diabetic dyslipidaemia: from basic research to clinical practice. *Diabetologia* 46:733–749, 2003
 12. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Häkkinen A, Olofson S-O, Yki-Järvinen H, Borén J: Overproduction of large VLDL particles is driven by increased liver fat content in man. *Diabetologia* 49:755–765, 2006
 13. Navab M, Anantharamaiah GM, Reddy ST, van Lenten BJ, Ansell BJ, Fogelmann AM: Mechanisms of disease: proatherogenic HDL: an evolving field. *Nat Clin Pract Endocrinol Metab* 2:504–511, 2006
 14. Rader DJ: Molecular regulation of HDL metabolism and function: implications for novel therapies. *J Clin Invest* 116:3090–3100, 2006
 15. Kontush A, Chapman MJ: Atherogenic small, dense HDL-guardian angel of the arterial wall? *Nat Clin Pract Cardiovasc Med* 3:144–153, 2006
 16. Groop PH, Thomas M, Rosengård-Bärlund M, Mills V, Rönnback M, Thomas S, Forsblom C, Taskinen MR, Viberti G: HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes. *Diabetes Care* 30:2706–2707, 2007
 17. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després J-P: Associations of HDL₂ and HDL₃ subfractions with ischemic heart disease in men. *Arterioscler Thromb Vasc Biol* 17:1098–1105, 1997
 18. Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ: Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in type 1 diabetes: a prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. *Diabetologia* 46: 674–682, 2003
 19. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, Fritsche A, Häring HU: High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. *Diabetes Care* 30:1173–1178, 2007
 20. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. *Am J Physiol Endocrinol Metab* 288:E462–E468, 2005
 21. Matsuda A, DeFronzo R: Insulin sensitivity indices obtained from oral glucose tolerance testing. *Diabetes Care* 22:1462–1470, 1999
 22. Patsch W, Brown SA, Morrisett JD, Gotto AM Jr, Patsch JR: A dual-precipitation method evaluated for measurement of cholesterol in high-density lipoprotein subfractions HDL₂ and HDL₃ in human plasma. *Clin Chem* 2:265–270, 1989
 23. Stefan N, Wahl HG, Fritsche A, Häring H, Stumvoll M: Effect of the pattern of elevated free fatty acids on insulin sensitivity and insulin secretion in healthy humans. *Horm Metab Res* 33:432–438, 2001
 24. Bagdade JD, Subbaiah PV: Abnormal high-density lipoprotein composition in women with insulin-dependent diabetes. *J Lab Clin Med* 113:235–40, 1989
 25. Nguyen SD, Sok DE: Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization. *Biochem J* 375:275–285, 2003